This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Eli Lilly (LLY) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Higher demand for its key drugs is likely to have offset generic competition for several other drugs and may have boosted Lilly's (LLY) second-quarter sales.
Amgen (AMGN) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Volume growth from Amgen's (AMGN) key drugs like Prolia, Xgeva, Repatha, and others is expected to have been partially offset by biosimilar/generic competition for mature drugs.
New Strong Sell Stocks for May 13th
by Zacks Equity Research
DDD, AMRN, and BDX have been added to the Zacks Rank #5 (Strong Sell) List on May 13, 2022.
Amarin (AMRN) Q1 Earnings & Sales Hurt by Vascepa Generics
by Zacks Equity Research
Amarin's (AMRN) Vascepa sales decline year over year amid rising generic competition and COVID-related disruptions during the first quarter. The company's stock falls significantly on May 4.
Amarin (AMRN) Q4 Earnings Top, Sales Hurt by Vascepa Generics
by Zacks Equity Research
Amarin's (AMRN) Vascepa sales decline amid rising generic competition and COVID-19 related disruptions during the fourth quarter. The company's stock falls on Mar 1, following the earnings release.
Amarin (AMRN) is a Top-Ranked Growth Stock: Should You Buy?
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why Amarin (AMRN) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Is the Options Market Predicting a Spike in Amarin (AMRN) Stock?
by Zacks Equity Research
Investors need to pay close attention to Amarin (AMRN) stock based on the movements in the options market lately.
Amarin (AMRN) Q3 Earnings Top, Vascepa Sales Decline Y/Y
by Zacks Equity Research
Amarin's (AMRN) reports lower sales volume for its drug, Vascepa, in the United States during the third quarter. The company's stock falls in pre-market trading.
All You Need to Know About Amarin (AMRN) Rating Upgrade to Strong Buy
by Zacks Equity Research
Amarin (AMRN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Amarin (AMRN) Q2 Earnings Top, Vascepa Strong Despite Generics
by Zacks Equity Research
Amarin's (AMRN) Vascepa sales benefit from increased demand in the United States during the second quarter. The drug retains majority market share in its segment amid rising generic competition. Stock up.
What's in the Cards for Amarin (AMRN) This Earnings Season?
by Zacks Equity Research
Amarin's (AMRN) second-quarter results are likely to reflect recovery in Vascepa sales amid potential recovery in COVID-19 related disruptions.
Amarin (AMRN) Q1 Earnings Top, Vascepa Sales Hit by COVID-19
by Zacks Equity Research
Amarin's (AMRN) Vascepa sales get hit by COVID-19 and by severe winter storms and power outages in various areas of the United States. Its cost management plan boost the bottom line. Stock up.
Amarin (AMRN) Q4 Earnings & Revenues Top, Vascepa Sales Solid
by Zacks Equity Research
Amarin's (AMRN) revenue growth in the fourth quarter is attributable to continued demand for its cardiovascular drug, Vascepa.
Amarin (AMRN) Surges: Stock Moves 9% Higher
by Zacks Equity Research
Amarin (AMRN) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Is the Options Market Predicting a Spike in Amarin (AMRN) Stock?
by Zacks Equity Research
Investors need to pay close attention to Amarin (AMRN) stock based on the movements in the options market lately.
Amarin's (AMRN) Q3 Earnings Lag, Sales In Line, Stock Down
by Zacks Equity Research
Amarin's (AMRN) revenue growth in the third quarter is attributable to continued demand for its cardiovascular drug, Vascepa. Generic competition for Vascepa seems imminent.
Are Options Traders Betting on a Big Move in Amarin (AMRN) Stock?
by Zacks Equity Research
Investors need to pay close attention to Amarin (AMRN) stock based on the movements in the options market lately.
Biotech Stock Roundup: GILD Submits BLA, ALBO Gains on Study Data & More
by Zacks Equity Research
The biotech sector remains in focus with regulatory and other pipeline updates.
Amarin Loses Patent Appeal in Vascepa Lawsuit, Stock Dips
by Zacks Equity Research
Amarin (AMRN) receives a setback as the U.S. Court of Appeals upholds a ruling by Nevada district court in favor of the generic companies related to patent litigation against Vascepa.
Are Options Traders Betting on a Big Move in Amarin (AMRN) Stock?
by Zacks Equity Research
Investors need to pay close attention to Amarin (AMRN) stock based on the movements in the options market lately.
Amarin (AMRN) in Focus: Stock Moves 5.5% Higher
by Zacks Equity Research
Amarin (AMRN) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Amarin (AMRN) Beats on Q2 Earnings, Focuses on Europe
by Zacks Equity Research
Amarin's (AMRN) revenue growth in the second quarter is attributable to continued demand for its cardiovascular drug, Vascepa.
Zomedica (ZOM) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Zomedica (ZOM) will provide an update on Truforma, its inaugural point-of-care diagnostic biosensor platform, when it reports second-quarter 2020 results
Aytu (AYTU) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Aytu (AYTU) will provide financial updates when it reports fourth-quarter fiscal 2020 results.